Plain-English translation of NCT06252675 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications— and —work better together to treat mantle cell lymphoma that has come back or stopped responding to earlier treatments. is given as an infusion through your vein, while is a pill you take by mouth. The study will watch how well this combination works and how safe it is.
Mantle cell lymphoma is a serious blood cancer, and when it returns or stops responding to standard treatments, patients have limited options. This trial exists to see whether this new combination of medications could offer hope to people in that difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive three medications: one as an intravenous infusion at the beginning, the second as an infusion in the first month, and the third as a daily pill. Treatment happens in 21-day cycles and could continue for up to 12 months if the cancer is responding well. You'll have regular scans and blood tests to monitor your progress, and a bone marrow biopsy around month 4.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States